Bio-Techne shares jumped 6.5% to close at $55.64 following investor optimism over potential drug-pricing agreements, despite a 22.2% decline year-to-date. The stock's performance aligns with broader market reactions to new initiatives from the Trump administration aimed at lowering prescription drug costs. Meanwhile, Avantor continues to struggle, with its stock down 41.1% this year after RBC Capital Markets lowered its price target.
Click a month on the chart to update the report below.
